Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Stem Cell-based Therapeutic and Diagnostic Approaches in Alzheimer's Disease

Abdi S., Javanmehr N., Ghasemi-Kasman M., Bali HY., Pirzadeh M.

Clinical Trial on Neuroinflammation, published in Curr Neuropharmacol (2022) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Curr Neuropharmacol (2022)
Reported sample size
—
Source database
Europe PMC
PMID
34970956
PMCID
PMC9886816
DOI
10.2174/1570159x20666211231090659
Citations
26

Abstract (original English)

Background Alzheimer's disease (AD) is a neurodegenerative impairment mainly recognized by memory loss and cognitive deficits. However, the current therapies against AD are mostly limited to palliative medications, prompting researchers to investigate more efficient therapeutic approaches for AD, such as stem cell therapy. Recent evidence has proposed that extensive neuronal and synaptic loss and altered adult neurogenesis, which is perceived pivotal in terms of plasticity and network maintenance, occurs early in the course of AD, which exacerbates neuronal vulnerability to AD. Thus, regeneration and replenishing the depleted neuronal networks by strengthening the endogenous repair mechanisms or exogenous stem cells and their cargoes is a rational therapeutic approach. Currently, several stem cell-based therapies as well as stem cell products like exosomes, have shown promising results in the early diagnosis of AD. Objective This review begins with a comparison between AD and normal aging pathophysiology and a discussion on open questions in the field. Next, summarizing the current stem cell-based therapeutic and diagnostic approaches, we declare the advantages and disadvantages of each method. Also, we comprehensively evaluate the human clinical trials of stem cell therapies for AD. Methodology Peer-reviewed reports were extracted through Embase, PubMed, and Google Scholar unt

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
NeuronsAnimalsHumansAlzheimer DiseaseStem Cell TransplantationNeurogenesis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research